Search | Clinical Trials Finder

Conditions: Wheezing, Asthma
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 14
States / cities: Phoenix, Arizona • Destin, Florida • Miami, Florida + 11 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 935 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 92
States / cities: Cullman, Alabama • Jasper, Alabama • Scottsboro, Alabama + 79 more

Conditions: Chronic Spontaneous Urticaria (CSU)
Interventions: Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 132
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 104 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 939 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 51
States / cities: Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 46 more

Conditions: Eosinophilic Esophagitis
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 62
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 54 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Dupilumab SAR231893, Placebo, non sedating H1-antihistamine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years to 80 Years
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 16
States / cities: Los Angeles, California • Sarasota, Florida • Sweetwater, Florida + 13 more

Conditions: Eosinophilic Esophagitis (EoE)
Interventions: Dupilumab, Matching Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 1 Year to 11 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 26
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 18 more

Conditions: Atopic Dermatitis (AD)
Interventions: Dupilumab, Placebo, Background treatment; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Chicago, Illinois • New York, New York • Dallas, Texas

Conditions: Asthma
Interventions: Dupilumab, Placebo; Drug · Other
Lead sponsor: Sally E. Wenzel MD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Peanut Allergy
Interventions: Dupilumab, Placebo matching dupilumab, AR101; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 25
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 21 more

Conditions: Eosinophilic Esophagitis
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 14
States / cities: Idaho Falls, Idaho • Chicago, Illinois • Urbana, Illinois + 11 more

Conditions: Asthma
Interventions: dupilumab, Matching placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 13
States / cities: Rolling Hills Estates, California • Torrance, California • Westminster, California + 10 more

Conditions: Dermatitis, Atopic
Interventions: Dupilumab, Matching Placebo, Background Treatment: Topical Corticosteroids, Background Treatment: Moisturizers; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 31
States / cities: Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 27 more

Conditions: Cold Urticaria
Interventions: Dupilumab SAR231893, Placebo, Non sedating H1-antihistamine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 5
States / cities: San Diego, California • Boise, Idaho • Owensboro, Kentucky + 2 more

Conditions: Allergic Bronchopulmonary Aspergillosis
Interventions: dupilumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 13
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 10 more

Conditions: Neurodermatitis
Interventions: Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Fort Smith, Arkansas • Sacramento, California • Pembroke Pines, Florida + 4 more

Conditions: Asthma
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years to 17 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 4 more

Conditions: Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis, Chronic Sinusitis, Sinus Disorder, Respiratory Disorder
Interventions: Dupilumab SAR231893, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 11
States / cities: Roseville, California • Stockton, California • Denver, Colorado + 7 more

Conditions: Asthma
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 1,339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 75
States / cities: Cullman, Alabama • Sheffield, Alabama • Chandler, Arizona + 66 more

Conditions: Allergic Rhinitis
Interventions: Dupilumab, Timothy Grass SCIT, Placebo matching dupilumab, Placebo matching SCIT; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 12
States / cities: Los Angeles, California • Mountain View, California • Walnut Creek, California + 9 more

Conditions: Aspirin-exacerbated Respiratory Disease
Interventions: Dupilumab; Drug
Lead sponsor: Rochester General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Asthma, Allergic
Interventions: REGN3500, Dupilumab, Placebo, Fluticasone propionate; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Cypress, California

Conditions: Bullous Pemphigoid
Interventions: dupilumab, Matching Placebo, Oral corticosteroids (OCS); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 15
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Redwood City, California + 12 more

Conditions: Allergic Fungal Rhinosinusitis
Interventions: Dupilumab SAR231893, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years and older
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 11
States / cities: Tampa, Florida • Atlanta, Georgia • Louisville, Kentucky + 7 more

Search by objective public record fields.

Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)

Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)

A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma

Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)

Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)

Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents

Dupilumab in CRSsNP

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy

Dupilumab for Aspirin-exacerbated Respiratory Disease

Study of REGN3500 and Dupilumab in Patients With Asthma

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid

Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI)